ATLASEnliven Therapeutics (ELVN) earnings date: Nov 11, 2026
Enliven Therapeutics (ELVN) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 11, 2026, after the close. Analysts expect EPS of -$0.48.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on ELVN
| Last price | $44.58 (+0.8%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.0% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Enliven Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Enliven Therapeutics reports on Nov 11, 2026. One email the day before, with ATLAS’s read on Enliven Therapeutics. You can switch it off at any time.
Alert me before ELVN reportsFree to start. Creating an account takes under a minute.
Notify me when Enliven Therapeutics reports
Track ELVN free Add Enliven Therapeutics to a free ATLAS watchlist and see its next report date in one place.
ELVN earnings at a glance
| Next report (confirmed) | Wed, Nov 11, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.48 |
| Last report | Aug 5, 2026 · Miss |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | -1.1% |
| Average move around a report | ±2.1% (last 5) |
| Sector | Healthcare · Biotechnology |
Enliven Therapeutics earnings history: last 5 reports
Enliven Therapeutics last reported on Aug 5, 2026: EPS of -$0.49 against an estimate of -$0.38 (-29.0% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 5, 2026 | -$0.38 | -$0.49 | -29.0% | Miss | -1.4% |
| May 7, 2026 | -$0.41 | -$0.38 | +7.3% | Beat | -1.1% |
| Apr 24, 2026 | $1.56 | $1.59 | +1.9% | In line | +2.3% |
| Mar 3, 2026 | -$0.47 | -$0.48 | -2.1% | Miss | +1.6% |
| Jan 23, 2026 | $1.61 | $1.87 | +16.2% | Beat | -4.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for ELVN
See the fair value, the probability range and the earnings history of Enliven Therapeutics on its ATLAS page.
Enliven Therapeutics (ELVN) stock analysisPlans from €3.99 a month.
Enliven Therapeutics earnings: frequently asked questions
When does Enliven Therapeutics (ELVN) report earnings?
Enliven Therapeutics is scheduled to report on Wednesday, November 11, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for ELVN?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.48 per share (USD). Estimates can change before the report.
How often does ELVN beat earnings estimates?
Of its last 5 reports with a recorded result, Enliven Therapeutics beat the EPS estimate 2 times; the average surprise was -1.1%. Past results do not predict the next one.
How much does ELVN move around earnings?
Over its last 5 reports the stock moved an average of 2.1% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Enliven Therapeutics beat earnings estimates last quarter?
Enliven Therapeutics last reported on Aug 5, 2026: EPS of -$0.49 against an estimate of -$0.38 (-29.0% surprise), a miss.
How much does ELVN usually move in a day?
On a normal trading day the ATLAS model puts ELVN’s one-day range at about ±3.0%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 11, 2026
Educational information, not investment advice. Disclaimer